Emergent announces U.S. FDA approved sNDA for OTC NARCAN nasal spray

Emergent BioSolutions (EBS) announced that the U.S. Food and Drug Administration, FDA, has approved its supplemental New Drug Application, sNDA, for over-the-counter, OTC, NARCAN Nasal Spray to be packaged in a new carrying case, which includes two blister packs, each enclosed with Quick Start Guide. “Every second counts in an opioid emergency, and our mission at Emergent is to ensure that life-saving tools like OTC NARCAN(R) Nasal Spray are readily available, easily accessible and are second nature to carry,” said Paul Williams, senior vice president, head of products business, global government and public affairs at Emergent. “In response to the ongoing opioid overdose epidemic, we believe this new carrying case is an additional option for our customers and consumers to acquire, while encouraging preparedness and expanding accessibility to help save lives.”